Title

Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension
D-dimer and the Use of Anticoagulation in IIH
  • Phase

    Early Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    48
Idiopathic intracranial hypertension (IIH) is a syndrome characterized by elevated intracranial pressure (ICP) of unknown etiology.

The investigators aim to study the quantitative D-dimer level and the role of anticoagulant therapy in the absence of occlusive sinus thrombosis in IIH patients.
24 patients with IIH according to the modified Dandy criteria were enrolled. Headache impact test (HIT6), ophthalmological assessment including Frisen classification for papilledema, visual acuity, visual field by perimetry, and visual evoked potentials were performed to the patients.

Serum quantitative D-dimer level was measured using the enzyme-linked immunosorbent assay (ELISA) technique for the patients and for 24 healthy matched controls.

Patients were divided into two groups: group (A) received acetazolamide and low molecular weight heparin (LMWH) in a prophylactic dose for 2 weeks while group (B) received acetazolamide only. Both groups continued the acetazolamide 1-2g/day for 6 months.

The investigators followed-up the patients after one and six months later through the HIT6 test and the ophthalmological assessment.
Study Started
Jul 22
2017
Primary Completion
Jul 23
2018
Study Completion
Aug 02
2018
Last Update
May 24
2019

Drug LMWH

Subcutaneous LMWH 1mg/kg/day for 2 weeks

  • Other names: Clexan

Drug acetazolamide

Carbonic anhydrase inhibitor 1-2g/day for 6 months

  • Other names: Diamox

Group A Active Comparator

12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)

Group B Active Comparator

12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)

Control group No Intervention

24 healthy subjects for whom serum D-dimer was assessed by ELISA.

Criteria

Inclusion Criteria:

IIH patients of both sexes fulfilling the modified Dandy criteria

Exclusion Criteria:

disturbed conscious level, focal neurological signs, seizures, cerebral venous sinus thrombosis or stenosis, deep venous thrombosis or pulmonary embolism, malignancy, and acute nephritic syndrome.
Patients with signs of disseminated intravascular coagulopathy and septic sinus thrombosis
patients with a history of cerebral granuloma or infection, cerebrovascular stroke, head trauma or surgery.
pregnant females or those who terminated their pregnancy in the last four weeks were also excluded.
No Results Posted